These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 26619140)

  • 21. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.
    Hirsch MS; Brun-Vézinet F; Clotet B; Conway B; Kuritzkes DR; D'Aquila RT; Demeter LM; Hammer SM; Johnson VA; Loveday C; Mellors JW; Jacobsen DM; Richman DD
    Clin Infect Dis; 2003 Jul; 37(1):113-28. PubMed ID: 12830416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The multiple benefits associated with HIV drug-resistance mutation M184V.
    Bean P
    Am Clin Lab; 2002 Mar; 21(2):16-8. PubMed ID: 11993249
    [No Abstract]   [Full Text] [Related]  

  • 23. Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain.
    de Mulder M; Yebra G; Martín L; Prieto L; Mellado MJ; Rojo P; Muñoz-Fernández MÁ; Jiménez de Ory S; Ramos JT; Holguín A;
    J Antimicrob Chemother; 2011 Oct; 66(10):2362-71. PubMed ID: 21810838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [HIV-1 resistance against antiretroviral agents].
    Asjø B; Ulvestad E
    Tidsskr Nor Laegeforen; 2001 Nov; 121(29):3421-4. PubMed ID: 11826790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic mechanisms of resistance to NRTI and NNRTI.
    Soriano V; de Mendoza C
    HIV Clin Trials; 2002; 3(3):237-48. PubMed ID: 12032883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiretroviral drug resistance testing.
    Sen S; Tripathy SP; Paranjape RS
    J Postgrad Med; 2006; 52(3):187-93. PubMed ID: 16855319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.
    Boender TS; Hoenderboom BM; Sigaloff KC; Hamers RL; Wellington M; Shamu T; Siwale M; Labib Maksimos EE; Nankya I; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Ondoa P; Rinke de Wit TF
    Clin Infect Dis; 2015 Dec; 61(11):1749-58. PubMed ID: 26240203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [AIDS treatment in Africa: the risk of antiretroviral resistance].
    Hamers RL; Schuurman R; van Vugt M; Derdelinckx I; Rinke de Wit TF
    Ned Tijdschr Geneeskd; 2007 Dec; 151(48):2666-71. PubMed ID: 18179083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug susceptibility to etravirine and darunavir among Human Immunodeficiency Virus Type 1-derived pseudoviruses in treatment-experienced patients with HIV/AIDS in South Korea.
    Kwon OK; Kim SS; Rhee JE; Kee MK; Park M; Oh HR; Choi JY
    Virol J; 2015 Apr; 12():53. PubMed ID: 25879840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis of HIV genotypic drug resistance among pediatric HIV/AIDS cases with virological failure after free antiretroviral therapy in Yunnan province].
    Zhong M; Yang S; Yang B; Liu J; Li J; Lou J; Li H
    Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(12):884-8. PubMed ID: 24854905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiretroviral drug resistance and HIV/AIDS in the developing world.
    Vella S
    J HIV Ther; 2002 Aug; 7(3):53-5. PubMed ID: 12442164
    [No Abstract]   [Full Text] [Related]  

  • 32. [Evolution and Diversity of HIV-1].
    Metzner KJ
    Praxis (Bern 1994); 2011 Jan; 100(1):29-35. PubMed ID: 21210358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV fusion inhibitors.
    Pozniak A
    J HIV Ther; 2001 Nov; 6(4):91-4. PubMed ID: 11740409
    [No Abstract]   [Full Text] [Related]  

  • 34. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Mechanisms of HIV-1 drug resistance to nucleoside and non-nucleoside reverse transcriptase inhibitors].
    Nikolenko GN; Kotelkin AT; Oreshkova SF; Il'ichev AA
    Mol Biol (Mosk); 2011; 45(1):108-26. PubMed ID: 21485502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance.
    Yin PD; Das D; Mitsuya H
    Cell Mol Life Sci; 2006 Aug; 63(15):1706-24. PubMed ID: 16715409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simple synthesis and anti-HIV activity of novel cyclopentene phosphonate nucleosides.
    Kim A; Hong JH
    Nucleosides Nucleotides Nucleic Acids; 2006; 25(1):1-8. PubMed ID: 16440980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No evidence for evolution of protease inhibitor resistance from standard genotyping, after three years of treatment with darunavir/ritonavir, with or without nucleoside analogues.
    Pulido F; Arribas J; Hill A; Moecklinghoff C
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1167-9. PubMed ID: 22380531
    [No Abstract]   [Full Text] [Related]  

  • 39. Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.
    Obiako OR; Murktar HM; Ogoina D
    Niger J Med; 2010; 19(4):352-60. PubMed ID: 21526620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefits and limitations of testing for resistance to HIV drugs.
    Richman DD
    J Antimicrob Chemother; 2004 Apr; 53(4):555-7. PubMed ID: 15014064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.